[go: up one dir, main page]

EA200401210A1 - Андрогенная фармацевтическая композиция и способ для лечения депрессии - Google Patents

Андрогенная фармацевтическая композиция и способ для лечения депрессии

Info

Publication number
EA200401210A1
EA200401210A1 EA200401210A EA200401210A EA200401210A1 EA 200401210 A1 EA200401210 A1 EA 200401210A1 EA 200401210 A EA200401210 A EA 200401210A EA 200401210 A EA200401210 A EA 200401210A EA 200401210 A1 EA200401210 A1 EA 200401210A1
Authority
EA
Eurasian Patent Office
Prior art keywords
depressive disorder
subject
androgenic
depression
treatment
Prior art date
Application number
EA200401210A
Other languages
English (en)
Other versions
EA007431B1 (ru
Inventor
Роберт И. Дадли
Доминик Друэн
Original Assignee
Юнимед Фармасьютикалз, Инк.
Лаборатуар Безен Энтернасьональ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/098,232 external-priority patent/US20040002482A1/en
Priority claimed from US10/153,468 external-priority patent/US20040092494A9/en
Application filed by Юнимед Фармасьютикалз, Инк., Лаборатуар Безен Энтернасьональ filed Critical Юнимед Фармасьютикалз, Инк.
Priority claimed from PCT/US2003/007910 external-priority patent/WO2004091631A1/en
Publication of EA200401210A1 publication Critical patent/EA200401210A1/ru
Publication of EA007431B1 publication Critical patent/EA007431B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Данное изобретение относится к способам, наборам, комбинациям и композициям для лечения, предупреждения или уменьшения риска развития депрессивного нарушения или симптомов, связанных с депрессивным нарушением или относящихся к депрессивному нарушению, у субъекта, нуждающегося в этом. Данное изобретение относится также к способу введения стероида в путь синтеза тестостерона, например тестостерона, субъекту, нуждающемуся в этом. Кроме того, эти способы, наборы, комбинации и композиции могут быть использованы вместе с другими фармацевтическими агентами, эффективными в лечении, предупреждении или уменьшении риска развития депрессивного нарушения у субъекта.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200401210A 2002-03-15 2003-03-14 Андрогенная фармацевтическая композиция и способ для лечения депрессии EA007431B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/098,232 US20040002482A1 (en) 2000-08-30 2002-03-15 Androgen pharmaceutical composition and method for treating depression
US10/153,468 US20040092494A9 (en) 2000-08-30 2002-05-21 Method of increasing testosterone and related steroid concentrations in women
PCT/US2003/007910 WO2004091631A1 (en) 2002-03-15 2003-03-14 Androgen pharmaceutical composition and method for treating depression

Publications (2)

Publication Number Publication Date
EA200401210A1 true EA200401210A1 (ru) 2005-08-25
EA007431B1 EA007431B1 (ru) 2006-10-27

Family

ID=34192609

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401210A EA007431B1 (ru) 2002-03-15 2003-03-14 Андрогенная фармацевтическая композиция и способ для лечения депрессии

Country Status (11)

Country Link
US (2) US20090318398A1 (ru)
AR (1) AR036970A1 (ru)
BR (1) BR0308584A (ru)
EA (1) EA007431B1 (ru)
IL (3) IL163981A0 (ru)
NO (1) NO345056B1 (ru)
NZ (1) NZ535368A (ru)
OA (1) OA12856A (ru)
TW (1) TWI339122B (ru)
UA (1) UA80964C2 (ru)
ZA (1) ZA200407403B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US8883769B2 (en) 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
ATE319426T1 (de) 2003-11-11 2006-03-15 Mattern Udo Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
DK3456329T3 (da) 2005-10-12 2025-02-24 Besins Healthcare Lu Sarl Forbedret testosteron-gel og fremgangsmåde til brug
US20100144687A1 (en) * 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
CA2818491A1 (en) 2010-11-18 2012-05-24 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
EP3922235A1 (en) * 2020-06-11 2021-12-15 Viramal Limited A hydroalcoholic gel and a method of manufacturing said gel
US12310974B1 (en) 2023-12-19 2025-05-27 Samuel Aballea Method of treating post-traumatic stress disorder with carpipramine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861764A (en) * 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
PH30747A (en) * 1989-03-10 1997-10-17 Endorech Inc Combination therapy for the treatment of estrogen sensitive disease.
US5788983A (en) * 1989-04-03 1998-08-04 Rutgers, The State University Of New Jersey Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
WO1996008229A2 (en) * 1994-09-14 1996-03-21 Minnesota Mining And Manufacturing Company Matrix for transdermal drug delivery
US5730987A (en) * 1996-06-10 1998-03-24 Omar; Lotfy Ismail Medication for impotence containing lyophilized roe and a powdered extract of Ginkgo biloba
US5760096A (en) * 1996-10-18 1998-06-02 Thornfeldt; Carl R. Potent penetration enhancers
US6019997A (en) * 1997-01-09 2000-02-01 Minnesota Mining And Manufacturing Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
WO1998034621A1 (en) * 1997-02-07 1998-08-13 Theratech, Inc. Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency
CA2309688C (en) * 1997-11-10 2007-04-24 Cellegy Pharmaceuticals, Inc. Penetration enhancing and irritation reducing systems
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
US5880117A (en) * 1998-07-13 1999-03-09 Arnold; Patrick Use of 4-androstenediol to increase testosterone levels in humans
ES2423899T3 (es) * 2000-08-30 2013-09-25 Unimed Pharmaceuticals, Llc Método para aumentar las concentraciones de testosterona y esteroides relacionados en las mujeres
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
FR2848112B1 (fr) * 2002-12-10 2007-02-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations
FR2851470B1 (fr) * 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
DK3456329T3 (da) * 2005-10-12 2025-02-24 Besins Healthcare Lu Sarl Forbedret testosteron-gel og fremgangsmåde til brug
US20090258063A1 (en) * 2006-09-11 2009-10-15 Sekisui Chemical Co., Ltd. Transdermal patch

Also Published As

Publication number Publication date
US20110306582A1 (en) 2011-12-15
IL163981A (en) 2011-11-30
IL215944A (en) 2014-09-30
TWI339122B (en) 2011-03-21
AR036970A1 (es) 2004-10-20
HK1082677A1 (zh) 2006-06-16
EA007431B1 (ru) 2006-10-27
IL163981A0 (en) 2005-12-18
US20090318398A1 (en) 2009-12-24
NO20044342L (no) 2004-12-06
NZ535368A (en) 2007-06-29
OA12856A (en) 2006-09-15
TW200412976A (en) 2004-08-01
ZA200407403B (en) 2007-09-26
NO345056B1 (no) 2020-09-07
IL215944A0 (en) 2011-12-29
UA80964C2 (en) 2007-11-26
BR0308584A (pt) 2005-02-22

Similar Documents

Publication Publication Date Title
EA200401210A1 (ru) Андрогенная фармацевтическая композиция и способ для лечения депрессии
DE60141587D1 (de) Verfahren zur behandlung von erektionsstörungen und steigerung der libido bei männern
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
BR0316203A (pt) Uso de um agente antialérgico e um esteróide para tratar rinite alérgica
CY1116779T1 (el) Αμιδο ενωσεις και η χρηση τους ως φαρμακευτικες ουσιες
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
EA200700251A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
MXPA05003621A (es) Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
ATE473242T1 (de) Therapeutische mittel welche einen bispezifischen anti-hla class ii invariant chain x anti-pathogen antikörper enthalten
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
DE60039783D1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DK1429756T3 (da) Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
EA202191736A1 (ru) Комбинированная терапия hbv
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
BR0314369A (pt) Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado
DE602004031356D1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
ATE443044T1 (de) Tace inhibitoren
ATE343398T1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title